Canada markets closed
  • S&P/TSX

    20,269.97
    +89.37 (+0.44%)
     
  • S&P 500

    4,305.20
    +8.06 (+0.19%)
     
  • DOW

    34,152.01
    +239.57 (+0.71%)
     
  • CAD/USD

    0.7787
    +0.0034 (+0.44%)
     
  • CRUDE OIL

    86.87
    -2.54 (-2.84%)
     
  • BTC-CAD

    30,749.42
    -364.85 (-1.17%)
     
  • CMC Crypto 200

    568.99
    -2.93 (-0.51%)
     
  • GOLD FUTURES

    1,790.70
    -7.40 (-0.41%)
     
  • RUSSELL 2000

    2,020.53
    -0.82 (-0.04%)
     
  • 10-Yr Bond

    2.8240
    +0.0330 (+1.18%)
     
  • NASDAQ

    13,102.55
    -25.50 (-0.19%)
     
  • VOLATILITY

    19.70
    -0.25 (-1.25%)
     
  • FTSE

    7,536.06
    +26.91 (+0.36%)
     
  • NIKKEI 225

    28,868.91
    -2.87 (-0.01%)
     
  • CAD/EUR

    0.7655
    +0.0030 (+0.39%)
     

Bluechiip Limited (BCT.AX) Quarterly Activities Report

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Bluechiip Limited
Bluechiip Limited

Bluechiip Limited (BCT.AX) Quarterly Activities Report

Melbourne, Australia, April 28, 2022 - (ABN Newswire) - Bluechiip Limited (ASX:BCT) (HAM:1BL), a leader in the development of advanced sample management solutions for harsh environments, is pleased to release the Group's Appendix 4C - Quarterly Cashflow report and update for the quarter ended 31 March 2022.

Corporate and Business updates for the Quarter

- Recorded sales for the quarter of $185k (of which $132k came in the month of March), and cash receipts of $109k;

- Delivery and installation of Bluechiip's new range of Bluechiip Enabled Advanced Sample Management solutions for orders from six customers since launch;

- Progressed growing the US sales and marketing team to target the North American market;

- Actively progressed Bluechiip's project with FujiFilm Irvine Scientific;

- Continued executing multiple active projects and negotiations with potential OEMs;

- Successfully granted a new Japanese Patent: Device, System and Method for Temperature Limit Indication and Detection of Temperature-Sensitive Items;

- Successfully granted the approval by AusIndustry for 2020-2021 research and development (R&D) registration to provide tax incentive cash refund of $1.1m; and

- Closing cash and cash equivalents of $2.79m as at 31 March 2022, with no borrowings.

*To view the full quarterly report, please visit:
https://abnnewswire.net/lnk/A59WF6SP


About Bluechiip Limited:


Bluechiip Limited (ASX:BCT) understands that every sample - stem cells, blood, eggs, sperm and other biospecimens - is critical, so our objective is to manage each one with optimal quality in the most efficient way. Bluechiip's advanced management solution is the only one that provides sample temperature with ID in cryogenic environments to. Most importantly, this delivers confidence in every sample.

Bluechiip's unique patented technology is a MEMS-based wireless tracking solution that contains no electronics. It represents a generational change from current tracking methods such as labels (hand-written and pre-printed), barcodes (linear and 2D), and Radio Frequency Identification. Bluechiip tags are either embedded or manufactured into storage products such as vials or bags. Each product can be easily identified, and critical information such as sample temperature, is detected by readers and stored in the Bluechiip software. In addition to functioning in extreme temperatures, the Bluechiip(R) Advanced Sample management solution can survive autoclaving, gamma irradiation sterilization, humidification, centrifuging, cryogenic storage and frosting.

Bluechiip's technology has applications in healthcare, including in cryogenic storage facilities (biobanks and biorepositories), pathology, clinical trials and forensics. Other key markets include cold-chain logistics/supply chain, security/defence, industrial/manufacturing and aerospace/aviation.

Bluechiip: Delivering confidence in every sample.

Contact:

Corporate enquiries
Andrew McLellan
Managing Director - CEO
Ph: +61-457-823-470
andrew.mclellan@bluechiip.com

Media
Richard Allen
Ph: +61-3-9915-6341
Oxygen Financial PR
richard@oxygenpr.com.au

Source:
Bluechiip Limited

Copyright (C) 2022 ABN Newswire. All rights reserved.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting